Human Genome Sciences, Pharmacia & Upjohn deal

The companies will develop antimicrobial therapeutic and diagnostic products using HGSI's gene sequences from Staphylococcus aureus and a pathogenic strain of Escherichia coli. Pharmacia & Upjohn will receive a non-exclusive license to use the gene sequences from S. aureus and E. coli together with HGSI's bioinformatics resources to identify targets and develop anti-infective, antibiotic and antifungal products.

The pharma company also has an option to obtain non-exclusive licenses to use genome sequences of other bacteria that HGSI may generate. ...